The Healthcare AI Revolution
AI companies transforming healthcare through drug discovery, diagnostics, medical imaging, and patient care.
AI is revolutionizing healthcare, from accelerating drug discovery to enabling more accurate diagnostics and personalized treatment.
Recursion Pharmaceuticals
Salt Lake City, United States
Recursion Pharmaceuticals leverages extensive biological and chemical datasets – exceeding 65 petabytes encompassing phenomics, transcriptomics, and patient data – to power its Recursion OS drug discovery platform. This platform utilizes computer vision, machine learning, and a proprietary supercomputer, BioHive-2, to analyze cellular images and predict drug efficacy, significantly accelerating hit identification and IND-enabling studies. Currently, Recursion is advancing a pipeline of potential therapies, including REC-3565 for B-cell lymphomas which is in Phase 1 clinical trials, and has established strategic partnerships with pharmaceutical and technology leaders to expand its AI-driven drug discovery capabilities.
Tempus AI
Chicago, United States
Tempus provides a platform combining comprehensive clinical and molecular data with artificial intelligence, primarily serving the oncology space. Their core offering is an operating system built upon the world’s largest library of such data, enhanced by recent advancements in generative AI like their clinical co-pilot, David, and digital pathology capabilities acquired through Paige. Tempus targets physicians, pharmaceutical companies, and patients seeking data-driven insights to improve cancer treatment decisions and accelerate drug development.
Babylon Health
London, United Kingdom
Babylon Health develops a platform offering AI-powered triage, remote consultations, and diagnostic tools, most notably through its Babylon 360 and GP at Hand services. Their core AI capabilities center on a deep learning system trained on millions of medical records to provide preliminary symptom assessment and risk prediction, alongside automated appointment scheduling and clinical note summarization. Initially focused on the UK’s National Health Service and direct-to-consumer offerings, Babylon has expanded internationally and achieved notable partnerships to deploy its technology in Rwanda and Canada, aiming to increase access to primary care.
Xaira Therapeutics
San Francisco, United States
Xaira Therapeutics is building a generative AI platform focused on de novo protein design and drug candidate creation, leveraging advancements from the technology behind AlphaFold. The company’s core innovation lies in applying AI to not just predict protein structures, but to generate novel protein therapeutics with optimized properties for a range of diseases. Backed by a $1 billion Series A funding round, Xaira Therapeutics aims to accelerate drug discovery beyond traditional methods and is initially focusing on developing therapeutics for currently undruggable targets.
Freenome
South San Francisco, United States
Freenome develops a blood-based, multiomics screening platform designed for early cancer detection, utilizing both genomic and proteomic biomarkers. Their core technology employs machine learning algorithms to analyze complex patterns in blood samples, aiming to detect cancer signals prior to symptom onset and improve screening accessibility. Currently focused on colorectal cancer with their CRC-DETECT test, Freenome is conducting clinical trials to validate performance and expand their platform to detect multiple cancer types, with a goal of increasing survival rates through earlier diagnosis.
Insitro
South San Francisco, United States
Insitro leverages high-throughput phenotypic screening and machine learning to build predictive models of human biology, focusing initially on diseases like NASH and heart failure. Their platform combines large-scale experimental data – including cellular assays and human genetic data – with proprietary machine learning algorithms to identify and validate drug targets and predict clinical trial success. Notably, Insitro has established collaborations with pharmaceutical companies like Bristol Myers Squibb and Roche to apply their technology to specific disease areas and advance novel therapeutics.
Collective Health
San Francisco, United States
Collective Health is a technology-enabled third-party administrator (TPA) that integrates and optimizes employee health benefits administration for self-funded employers. Their platform utilizes data analytics and AI-driven personalization to connect medical, pharmacy, and ancillary benefits into a single, user-friendly experience. This solution aims to reduce administrative costs and improve member engagement by providing a simplified and connected benefits journey for employers and their employees.
Zipline
South San Francisco, United States
Zipline Rwanda operates an autonomous drone delivery service focused on rapidly distributing critical medical supplies, including blood and vaccines, to remote and underserved healthcare facilities. Their core technology is a fully integrated platform encompassing drone aircraft, automated logistics software, and a proprietary demand forecasting system to optimize inventory and delivery routes. Targeting the healthcare sector and governments in regions with challenging infrastructure, Zipline provides instant, reliable access to essential medical products, reducing delivery times and improving health outcomes.
Butterfly Network
Burlington, United States
Butterfly Network develops handheld, whole-body ultrasound devices integrated with AI-powered software for point-of-care imaging. Their flagship product, the Butterfly iQ3, utilizes a single probe to deliver diagnostic imaging across a wide range of clinical applications. Butterfly Network serves diverse markets including individual medical practices, large healthcare systems, and medical education programs, offering a portable and accessible alternative to traditional ultrasound technology.
iCarbonX
Shenzhen, China
iCarbonX develops a comprehensive digital health platform, utilizing its core product, the iCarbonX Apollo system, to integrate multi-omics data – including genomics, metabolomics, and microbiome analysis – with data from wearable sensors and user-reported health information. Their AI capabilities focus on developing predictive models for disease risk assessment and personalized health management, leveraging deep learning algorithms to identify biomarkers and patterns indicative of early-stage health concerns. Initially focused on the Chinese market, iCarbonX aims to provide preventative healthcare solutions and has notably partnered with hospitals and research institutions to validate its AI-driven health insights.